Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vistusertib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vistusertib is an orally bioavailable small molecule inhibitor of the mammalian target of rapamycin (mTOR), specifically acting as a dual inhibitor of both mTORC1 and mTORC2 complexes. By inhibiting mTOR, a serine/threonine kinase involved in the PI3K/Akt/mTOR signaling pathway, vistusertib can induce tumor cell apoptosis and decrease tumor cell proliferation. It was developed for potential antineoplastic activity across various cancers, including advanced gastric adenocarcinoma, breast cancer, ovarian cancer, lung cancer, renal carcinoma, diffuse large B-cell lymphoma, meningioma, and others. Vistusertib has demonstrated blood-brain barrier penetration and has been evaluated in combination with other therapies such as paclitaxel or aromatase inhibitors[1][2][3][4][6][7].
- Brand names
- vistusertib
- Other names
- vistusertib [INN]
02
Targets
Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on vistusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vistusertib.